Why the study?
Does ORG 10172 alter coagulation parameters and pharmacokinetics compared to heparin and placebo in healthy male subjects?
Population
83 healthy male subjects
Comparison
Intravenous bolus injections of ORG 10172 vs Placebo and heparin injections (5000 units)
Authors
Loading...
Longer half-life versus heparin supports dosing studies; leaves open efficacy and safety in patients.
Does ORG 10172 alter coagulation parameters and pharmacokinetics compared to heparin and placebo in healthy male subjects?
ORG 10172 is a low molecular weight heparinoid with a longer half-life and different pharmacodynamic profile compared to standard heparin, supporting its potential as a long-acting anticoagulant.
Bradbrook et al. (1987) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: